Back to top
more

Exact Sciences (EXAS)

(Delayed Data from NSDQ)

$69.80 USD

69.80
2,470,028

+0.87 (1.26%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $69.80 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

by Zacks Equity Research

Sector ETF report for FBT

Here's How Much You'd Have If You Invested $1000 in Exact Sciences a Decade Ago

by Zacks Equity Research

Holding on to popular or trending stocks for the long-term can make your portfolio a winner.

The Zacks Analyst Blog Highlights Jinko Solar, American Airlines and Exact Sciences

by Zacks Equity Research

Jinko Solar, American Airlines and Exact Sciences are included in this Analyst Blog.

Exact Sciences (EXAS) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Exact Sciences (EXAS) closed at $68.54 in the latest trading session, marking a +1.99% move from the prior day.

Derek Lewis headshot

3 Top Stocks Already up More Than 20% In 2023

by Derek Lewis

While inflation remains the market's primary concern, these three stocks have gotten off to a great start in 2023, already up more than 20% year-to-date. Can the strength continue? Their earnings outlooks suggest so.

Should iShares Morningstar SmallCap ETF (ISCB) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for ISCB

Zacks Market Edge Highlights: EXAS, ZM, TSLA, ABBV, ZOM

by Zacks Equity Research

EXAS, ZM, TSLA, ABBV, ZOM have been highlighted in this Market Edge article.

Tracey Ryniec headshot

The Stocks Behind 2022's Popular ETFs

by Tracey Ryniec

What stocks do popular ETF managers like Cathie Wood own in their portfolios?

Here's Why Investors Should Buy Exact Sciences (EXAS) Stock

by Zacks Equity Research

Investors are optimistic about Exact Sciences (EXAS) on continued strength across the Screening and Precision Oncology businesses.

Strength Seen in Exact Sciences (EXAS): Can Its 24.7% Jump Turn into More Strength?

by Zacks Equity Research

Exact Sciences (EXAS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Is Bionano Genomics (BNGO) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Bionano Genomics, Inc. (BNGO) and Exact Sciences (EXAS) have performed compared to their sector so far this year.

3 Reasons to Retain Surmodics (SRDX) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.

Derek Lewis headshot

3 Hot Mid-Caps During a Cold December

by Derek Lewis

Despite the market's cold performance in December, these three stocks have remained hot, snapping the bearish trend. Their earnings outlooks suggest even more upside in 2023.

3 Reasons to Retain Nevro (NVRO) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Nevro (NVRO), owing to its R&D edge.

3 Reasons to Retain Glaukos (GKOS) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Glaukos (GKOS) on the back of continued strength in its flagship iStent.

3 Reasons to Retain OPKO Health (OPK) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in RAYALDEE.

3 Reasons to Retain Inogen (INGN) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.

McKesson (MCK) Announces Availability of FDA-Accepted Drug

by Zacks Equity Research

The availability of FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for PEComa.

3 Reasons to Retain Abiomed (ABMD) Stock in Your Portfolio

by Zacks Equity Research

Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.

Here's Why You Should Retain NextGen (NXGN) Stock for Now

by Zacks Equity Research

NextGen's (NXGN) strong product portfolio and continued demand for its solutions raise optimism about the stock.

McKesson (MCK) Announces Availability of FDA-Approved Drug

by Zacks Equity Research

The availability of FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for AML.

Here's Why You Should Retain Abbott (ABT) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Abbott (ABT) owing to the strength in its Diabetes business and product launches.

QuidelOrtho's (QDEL) Myocardial Infarction Test Cleared in Canada

by Zacks Equity Research

QuidelOrtho's (QDEL) TriageTrue hsTnl Test is to be used to diagnose myocardial infarction following Health Canada's approval.

QuidelOrtho's (QDEL) Latest JV to Boost Footprint in China

by Zacks Equity Research

QuidelOrtho's (QDEL) new JV will likely translate into a faster time-to-market and a more compelling menu for VITROS assays in support of its growth strategy in China and beyond.